News
Hosted on MSN1mon
Vivace closes $35m in Series D for cancer drug developmentVT3989 is a transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor ... with a focus on treating mesothelioma. The small-molecule cancer drug has already been assessed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback